Business Context and Reporting Period
This Form 8-K was filed by Intrexon Corporation on June 29, 2016, reporting a material definitive agreement entered into with ZIOPHARM Oncology, Inc. (ZIOPHARM). The filing details amendments to existing collaboration agreements regarding cancer treatment and graft-versus-host disease (GvHD) programs, alongside a new securities issuance agreement.
Key Financial Metrics and Transaction Terms
The filing does not provide standard financial metrics such as revenue, profit, cash flow, or debt levels for Intrexon. Instead, it outlines specific financial terms of the new agreement:
- Royalty Reduction: ZIOPHARM's royalty payments to Intrexon on net profits from the Cancer Program and GvHD Program are reduced from 50% to 20% on a quarterly basis.
- Consideration: In exchange for the royalty reduction, ZIOPHARM issued 100,000 shares of Series 1 Preferred Stock to Intrexon.
- Preferred Stock Value: Each share has a stated value of $1,200, totaling $120,000 in stated value.
- Dividend Rights: Holders receive a monthly dividend of $12.00 per share (payable in additional preferred shares). This rate automatically increases to $24.00 per share per month if the shares are not converted by the Conversion Event Date.
Material Changes Versus Prior Period
The primary material change is the restructuring of the revenue-sharing model between Intrexon and ZIOPHARM. The royalty rate on net profits for both the Cancer Program and the GvHD Program was significantly lowered from 50% to 20%. This change was compensated by the issuance of preferred equity rather than immediate cash consideration.
Guidance, Outlook, and Material Terms
The filing outlines specific conditions for the preferred stock issued to Intrexon:
- Conversion Trigger: The preferred shares automatically convert into ZIOPHARM common stock upon the first public announcement of U.S. approval for a product under the Cancer Program, GvHD Program, or a related License and Collaboration Agreement.
- Conversion Limitation: Conversion is capped at 19.9% of the lesser of pre-transaction outstanding shares or shares outstanding at the time of conversion, unless stockholder approval is obtained.
- Liquidation Rights: In the event of a liquidation or "Deemed Liquidation Event" (including change of control), holders are entitled to a pro-rata share of funds based on an as-converted common stock basis.
- Voting Rights: Holders generally lack voting rights but possess protective rights regarding amendments to the Certificate of Incorporation, issuance of senior securities, or transactions adversely affecting their class.
Important Facts for Investor Verification
- Verify the current status of ZIOPHARM's product development pipelines for cancer and GvHD to assess the likelihood of the "Conversion Event."
- Review the "net profits" calculation methodology in the amended agreements to understand the impact of the 20% royalty rate versus the previous 50% rate.
- Monitor ZIOPHARM's stock price and outstanding share count to calculate the potential dilution impact of the preferred stock conversion.
- Confirm whether the 19.9% conversion limitation will require future stockholder approval if ZIOPHARM's share count changes significantly prior to conversion.